Galmed (GLMD) announced the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra for the treatment of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and liver fibrosis in South Korea. Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals’ Rezdiffra for MASH. The new patent extends Aramchol’s patent protection worldwide to July 2042.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLMD:
- Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position
- Galmed issues CEO letter to shareholders
- Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs
- Galmed reports Q3 EPS (33c) vs. ($2.31) last year
- Galmed reports ‘meaningful’ results from AM-001 study of Aramchol meglumine